Reference values for forced vital capacity in idiopathic pulmonary fibrosis

被引：0
作者：
Pereira, Carlos A. C. [1 ]
机构：
[1] Univ Fed Sao Paulo, Interstitial Lung Dis Program, Sao Paulo, Brazil
来源：
RESPIRATORY MEDICINE | 2017年 / 125卷
关键词：
D O I：
10.1016/j.rmed.2016.11.022
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：102 / 102
页数：1
相关论文
共 5 条
  • [1] Degens P, 2008, EUR RESPIR J, V31, P687, DOI 10.1183/09031936.00145507
  • [2] Duarte Andrezza Araújo de Oliveira, 2007, J. bras. pneumol., V33, P527, DOI 10.1590/S1806-37132007000500007
  • [3] Kolb M., 2016, NINTEDANIB PATIENTS
  • [4] Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
    Richeldi, Luca
    du Bois, Roland M.
    Raghu, Ganesh
    Azuma, Arata
    Brown, Kevin K.
    Costabel, Ulrich
    Cottin, Vincent
    Flaherty, Kevin R.
    Hansell, David M.
    Inoue, Yoshikazu
    Kim, Dong Soon
    Kolb, Martin
    Nicholson, Andrew G.
    Noble, Paul W.
    Selman, Moises
    Taniguchi, Hiroyuki
    Brun, Michele
    Le Maulf, Florence
    Girard, Mannaig
    Stowasser, Susanne
    Schlenker-Herceg, Rozsa
    Disse, Bernd
    Collard, Harold R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) : 2071 - 2082
  • [5] Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predicted
    Ward, Katie
    Spurr, Lydia
    Goldman, Nina R.
    Margaritopoulos, George A.
    Kokosi, Maria
    Renzoni, Elizabetta
    Chua, Felix
    Maher, Toby M.
    Ward, Simon
    Wells, Athol U.
    [J]. RESPIRATORY MEDICINE, 2016, 120 : 131 - 133
1